FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590059573> ?p ?o ?g. }

• W2590059573 endingPage "92" @default.
• W2590059573 startingPage "92" @default.
• W2590059573 abstract "92 Background: Docetaxel (DOC) represents the treatment of choice in the first line treatment for patients (pts) with castration-resistant prostate cancer (CRPC). However, when CRPC is diagnosed in pts age 80 or older, the fear of high toxicity degree usually limits chemotherapy use due to both pts frailty and several comorbidities occurrence. The present retrospective study is aimed to assess the clinical outcomes in this very elderly CRPC population. Methods: In this multicentric retrospective study, after Ethical Committee approval, we have reviewed the clinical records of all pts age 80 and older CRPC pts from participating institutions, treated with DOC in clinical practice, recording the pre- and post-DOC clinical history, the DOC treatment details and outcomes. Results: To date we collected a consecutive series of 115 pts from 28 Italian hospitals. The median age was 82 (range 80 to 90). The median baseline prostate-specific antigen (PSA) was 92 ng/ml (range 3 to 2,981); 83% of the pts had bone metastases, while nodal, lung and liver metastases were observed in 39%, 9%, and 8% of the pts, respectively. Median Cumulative Illness Rating Scale score was 3 (range 0 to 11), median Activity Daily Living index score was 0 (range 0 to 5), median Instrumental Activities of Daily Living score was 0 (range 0 to 5). The DOC was administered on 3 week or weekly schedule basis (43%/57%). A PSA reduction greater than 50% was observed in 55% of the pts; an objective response was observed in 15% of the 60 pts who underwent a radiological re-evaluation at the treatment end. Grade 3-4 toxicities were: anemia (2%), neutropenia (10%) , thrombocytopenia (2%), fatigue (10%), diarrhea (4%), nausea (2%), renal (2%), and febrile neutropenia (2%). The median progression-free survival (PFS) and overall survival (OS )were 7 months and 20 months, while the 1 year PFS and OS rates were 21.2% and 71.5%, respectively. Conclusions: This data suggests that selected very older (age 80 and older) CRPC pts may received DOC with a good toxicity profile. In this pts population the treatment, both on 3 week or weekly schedule, is able to produce survival outcomes comparable to pivotal trials (18 months)." @default.
• W2590059573 created "2017-03-03" @default.
• W2590059573 creator A5004001131 @default.
• W2590059573 creator A5018378600 @default.
• W2590059573 creator A5018762049 @default.
• W2590059573 creator A5021477057 @default.
• W2590059573 creator A5021690836 @default.
• W2590059573 creator A5023171492 @default.
• W2590059573 creator A5025051235 @default.
• W2590059573 creator A5025797878 @default.
• W2590059573 creator A5030122361 @default.
• W2590059573 creator A5030571299 @default.
• W2590059573 creator A5046205568 @default.
• W2590059573 creator A5055092713 @default.
• W2590059573 creator A5055464636 @default.
• W2590059573 creator A5057926104 @default.
• W2590059573 creator A5059003996 @default.
• W2590059573 creator A5070073727 @default.
• W2590059573 creator A5073892178 @default.
• W2590059573 creator A5075400298 @default.
• W2590059573 creator A5078567479 @default.
• W2590059573 creator A5082704939 @default.
• W2590059573 date "2014-02-01" @default.
• W2590059573 modified "2023-10-18" @default.
• W2590059573 title "Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study)." @default.
• W2590059573 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.92" @default.
• W2590059573 hasPublicationYear "2014" @default.
• W2590059573 type Work @default.
• W2590059573 sameAs 2590059573 @default.
• W2590059573 citedByCount "2" @default.
• W2590059573 countsByYear W25900595732017 @default.
• W2590059573 countsByYear W25900595732021 @default.
• W2590059573 crossrefType "journal-article" @default.
• W2590059573 hasAuthorship W2590059573A5004001131 @default.
• W2590059573 hasAuthorship W2590059573A5018378600 @default.
• W2590059573 hasAuthorship W2590059573A5018762049 @default.
• W2590059573 hasAuthorship W2590059573A5021477057 @default.
• W2590059573 hasAuthorship W2590059573A5021690836 @default.
• W2590059573 hasAuthorship W2590059573A5023171492 @default.
• W2590059573 hasAuthorship W2590059573A5025051235 @default.
• W2590059573 hasAuthorship W2590059573A5025797878 @default.
• W2590059573 hasAuthorship W2590059573A5030122361 @default.
• W2590059573 hasAuthorship W2590059573A5030571299 @default.
• W2590059573 hasAuthorship W2590059573A5046205568 @default.
• W2590059573 hasAuthorship W2590059573A5055092713 @default.
• W2590059573 hasAuthorship W2590059573A5055464636 @default.
• W2590059573 hasAuthorship W2590059573A5057926104 @default.
• W2590059573 hasAuthorship W2590059573A5059003996 @default.
• W2590059573 hasAuthorship W2590059573A5070073727 @default.
• W2590059573 hasAuthorship W2590059573A5073892178 @default.
• W2590059573 hasAuthorship W2590059573A5075400298 @default.
• W2590059573 hasAuthorship W2590059573A5078567479 @default.
• W2590059573 hasAuthorship W2590059573A5082704939 @default.
• W2590059573 hasConcept C121608353 @default.
• W2590059573 hasConcept C126322002 @default.
• W2590059573 hasConcept C141071460 @default.
• W2590059573 hasConcept C143998085 @default.
• W2590059573 hasConcept C167135981 @default.
• W2590059573 hasConcept C2776907518 @default.
• W2590059573 hasConcept C2777899217 @default.
• W2590059573 hasConcept C2778971682 @default.
• W2590059573 hasConcept C2780192828 @default.
• W2590059573 hasConcept C2781190966 @default.
• W2590059573 hasConcept C2908647359 @default.
• W2590059573 hasConcept C71924100 @default.
• W2590059573 hasConcept C99454951 @default.
• W2590059573 hasConceptScore W2590059573C121608353 @default.
• W2590059573 hasConceptScore W2590059573C126322002 @default.
• W2590059573 hasConceptScore W2590059573C141071460 @default.
• W2590059573 hasConceptScore W2590059573C143998085 @default.
• W2590059573 hasConceptScore W2590059573C167135981 @default.
• W2590059573 hasConceptScore W2590059573C2776907518 @default.
• W2590059573 hasConceptScore W2590059573C2777899217 @default.
• W2590059573 hasConceptScore W2590059573C2778971682 @default.
• W2590059573 hasConceptScore W2590059573C2780192828 @default.
• W2590059573 hasConceptScore W2590059573C2781190966 @default.
• W2590059573 hasConceptScore W2590059573C2908647359 @default.
• W2590059573 hasConceptScore W2590059573C71924100 @default.
• W2590059573 hasConceptScore W2590059573C99454951 @default.
• W2590059573 hasIssue "4_suppl" @default.
• W2590059573 hasLocation W25900595731 @default.
• W2590059573 hasOpenAccess W2590059573 @default.
• W2590059573 hasPrimaryLocation W25900595731 @default.
• W2590059573 hasRelatedWork W122177069 @default.
• W2590059573 hasRelatedWork W1652439388 @default.
• W2590059573 hasRelatedWork W2021751111 @default.
• W2590059573 hasRelatedWork W2094570582 @default.
• W2590059573 hasRelatedWork W2135620818 @default.
• W2590059573 hasRelatedWork W2299690226 @default.
• W2590059573 hasRelatedWork W2568045406 @default.
• W2590059573 hasRelatedWork W2735900144 @default.
• W2590059573 hasRelatedWork W2776356588 @default.
• W2590059573 hasRelatedWork W2795222586 @default.
• W2590059573 hasVolume "32" @default.
• W2590059573 isParatext "false" @default.
• W2590059573 isRetracted "false" @default.
• W2590059573 magId "2590059573" @default.
• W2590059573 workType "article" @default.